|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | C07D 487/04 | (2006.01) |
| A61K 31/519 | (2006.01) | ||
| A61P 29/00 | (2006.01) |
| (11) | Number of the document | 3483163 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18206943.5 |
| Date of filing the European patent application | 2014-09-03 | |
| (97) | Date of publication of the European application | 2019-05-15 |
| (45) | Date of publication and mention of the grant of the patent | 2021-06-23 |
| (46) | Date of publication of the claims translation | 2021-09-10 |
| (30) | Number | Date | Country code |
| 13183385 | 2013-09-06 | EP |
| (72) |
ROEVER, Stephan , DE
ROGERS-EVANS, Mark , CH
NETTEKOVEN, Matthias , DE
SCHMITT, Sébastien , FR
GRETHER, Uwe , DE
KIMBARA, Atsushi , JP
|
| (73) |
F. Hoffmann-La Roche AG ,
Grenzacherstrasse 124, 4070 Basel,
CH
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Triazol[4,5-d]pirimidino dariniai kaip CB2 receptorių antagonistai |
| TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES AS CB2 RECEPTOR ANTAGONISTS |
| Payment date | Validity (years) | Amount | |
| 2023-08-22 | 10 | 231.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2024-09-03 |